NEO-Match nanomechanical testing of pancreatic tumor samples

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm study at Moffitt Cancer Center collects one extra biopsy sample during routine pancreatic biopsy or surgery for analysis with the ARTIDIS ART-1 atomic force microscopy device. The ART-1 measures nanomechanical properties of fresh tissue to generate a NEO-Match® score, which will be compared with standard histopathology, imaging findings, and clinical outcomes including response to neoadjuvant therapy. Participation is integrated into standard clinical workflow and does not alter or delay care. Researchers aim to see if nanomechanical profiling can improve diagnostic accuracy and predict treatment response in pancreatic ductal adenocarcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Ability to understand and willingness to sign a written informed consent form
* Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy

Exclusion Criteria:

* Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting

Study contacts

• Study coordinator: Julia Ortega, DMSc, MHS, PA
• Email: julia.ortega@artidis.com
• Phone: 2404980176

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Energy needs after pancreatic surgery: measuring metabolism to guide nutrition

  This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.

  Recruiting Evangelismos Hospital · Athens, Attica · NCT07703813

• Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions

  This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.

  Recruiting Alexandria University · Alexandria · NCT07656571

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Pancreatic Cancer Screen Test in Japan Using the Enzeavour Blood Assay

  This nationwide screening study in Japan tests the Enzeavour Pancreatic Cancer blood test in about 10,000 asymptomatic adults to see if it can help detect pancreatic cancer early.

  Recruiting at 69 sites Cosomil, Inc. · Nagakute, Aichi-ken and 68 other locations · NCT07605819

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.